参考文献/References:
[1]Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin,2021,71(3):209-249.[2]Reck M,Rodríguez-Abreu D,Robinson AG,et al.Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J].N Engl J Med,2016,375(19):1823-1833.[3]Hanahan D,Weinberg RA.Hallmarks of cancer: the next generation[J].Cell,2011,144(5):646-674.[4]Mjaess G,Chebel R,Karam A,et al.Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in urological tumors: an umbrella review of evidence from systematic reviews and meta-analyses[J].Acta Oncol,2021,60(6):704-713.[5]Moldoveanu D,Pravongviengkham V,Best G,et al.Dynamic Neutrophil-to-Lymphocyte Ratio: A Novel Prognosis Measure for Triple-Negative Breast Cancer[J].Ann Surg Oncol,2020,27(10):4028-4034.[6]Iwai N,Okuda T,Sakagami J,et al.Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer[J].Sci Rep,2020,10(1):18758.[7]Takada K,Takamori S,Yoneshima Y,et al.Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy[J].Lung Cancer,2020,145:18-26.[8]Suh KJ,Kim SH,Kim YJ,et al.Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody[J].Cancer Immunol Immunother,2018,67(3):459-470.[9]Zhao X,Zhang N,Zhang H,et al.High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments[J].Medicine (Baltimore),2020,99(46):e23150.[10]Takeda T,Takeuchi M,Saitoh M,et al.Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer[J].Thorac Cancer,2018,9(10):1291-1299.[11]Song P,Yang D,Cui X,et al.NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score[J].Cancer Manag Res,2020,12:5975-5985.[12]Shiroyama T,Suzuki H,Tamiya M,et al.Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer[J].Cancer Med,2018,7(1):13-20.[13]Russo A,Russano M,Franchina T,et al.Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study[J].Adv Ther,2020,37(3):1145-1155.[14]Prelaj A,Ferrara R,Rebuzzi SE,et al.EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort[J].Cancers (Basel),2019,11(12):1954.[15]Peng L,Wang Y,Liu F,et al.Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors[J].Cancer Immunol Immunother,2020,69(9):1813-1822.[16]Matsubara T,Takamori S,Haratake N,et al.The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab[J].J Thorac Dis,2020,12(4):1520-1528.[17]Liu J,Li S,Zhang S,et al.Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab[J].J Clin Lab Anal,2019,33(8):e22964.[18]Ksienski D,Wai ES,Alex D,et al.Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab[J].Transl Lung Cancer Res,2021,10(1):355-367.[19]Katayama Y,Yamada T,Chihara Y,et al.Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients[J].Sci Rep,2020,10(1):17495.[20]Ichiki Y,Taira A,Chikaishi Y,et al.Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors[J].J Thorac Dis,2019,11(4):1117-1123.[21]Hasegawa T,Yanagitani N,Utsumi H,et al.Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer[J].Anticancer Res,2019,39(12):6851-6857.[22]Fukui T,Okuma Y,Nakahara Y,et al.Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study[J].Clin Lung Cancer,2019,20(3):208-214.e2.[23]Facchinetti F,Veneziani M,Buti S,et al.Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab[J].Immunotherapy,2018,10(8):681-694.[24]Dusselier M,Deluche E,Delacourt N,et al.Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers[J].PLoS One,2019,14(7):e0219060.[25]Dragomir R,Dragomir AS,Negru A,et al.Role of combining neutrophil-to-lymphocyte ratio and pretreatment body mass index in predicting progression-free survival in patients with non-small cell lung cancer treated with nivolumab[J].Exp Ther Med,2021,21(5):526. [26]Diem S,Schmid S,Krapf M,et al.Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab[J].Lung Cancer,2017,111:176-181.[27]Chen S,Li R,Zhang Z,et al.Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors[J].Transl Lung Cancer Res,2021,10(3):1397-1407.[28]Bagley SJ,Kothari S,Aggarwal C,et al.Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer[J].Lung Cancer,2017,106:1-7.[29]Pavan A,Calvetti L,Dal Maso A,et al.Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors[J].Oncologist,2019,24(8):1128-1136.[30]Park W,Kwon D,Saravia D,et al.Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab[J].Clin Lung Cancer,2018,19(3):280-288.e4.[31]M?觟ller M,Turzer S,Schütte W,et al.Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade[J].J Immunother,2020,43(2):57-66.[32]Giustini N,Bazhenova L.Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)[J].Lung Cancer (Auckl),2021,12:21-34.[33]Cao D,Xu H,Xu X,et al.A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies[J].Oncoimmunology,2018,7(11):e1507262.[34]Grecian R,Whyte MKB,Walmsley SR.The role of neutrophils in cancer[J].Br Med Bull. 2018,128(1):5-14.[35]Treffers LW,Hiemstra IH,Kuijpers TW,et al.Neutrophils in cancer[J].Immunol Rev,2016,273(1):312-328.[36]Borst J,Ahrends T,B?諭ba?覥a N,et al.CD4+ T cell help in cancer immunology and immunotherapy[J].Nat Rev Immunol,2018,18(10):635-647.
相似文献/References:
[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(07):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(07):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]陈学敏,彭 琼.中性粒细胞与淋巴细胞比值联合癌胚抗原对结直肠癌早期诊断的研究[J].医学信息,2019,32(02):75.[doi:10.3969/j.issn.1006-1959.2019.02.022]
CHEN Xue-min,PENG Qiong.Early Diagnosis of Colorectal Cancer by Neutrophil-lymphocyte Ratio Combined with Carcinoembryonic Antigen[J].Journal of Medical Information,2019,32(07):75.[doi:10.3969/j.issn.1006-1959.2019.02.022]
[4]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的
表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(07):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[5]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(07):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[6]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(07):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[7]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(07):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[8]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(07):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[9]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(07):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[10]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Journal of Medical Information,2022,35(07):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[11]曹鸣菲,雷德财,董秋月,等.NSCLC患者外周血血小板相关参数与临床病理特征的关系[J].医学信息,2023,36(18):90.[doi:10.3969/j.issn.1006-1959.2023.18.016]
CAO Ming-fei,LEI De-cai,DONG Qiu-yue,et al.The Relationship Between Peripheral Blood Platelet Related Parameters and Clinicopathological Features in NSCLC Patients[J].Journal of Medical Information,2023,36(07):90.[doi:10.3969/j.issn.1006-1959.2023.18.016]